Clinical results show that raloxlfene benefits heart and bone in postmenopausal women without increasing the risk of uterine cancer but its long-term effects are unknown.
|Original language||English (US)|
|Number of pages||2|
|State||Published - 1998|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)